MTOR and malignant colon neoplasm: The genetic variation in a candidate pathway contributes to the risk of both colon and rectal cancers, and protein kinase AMP-activated non-catalytic subunit gamma 2 (PRKAG2), mechanistic target of rapamycin kinase (FRAP1), TSC complex subunit 2 (TSC2), and protein kinase AMP-activated catalytic subunit alpha 1 (PRKAA1) genes involved in the pathway are significantly related to colon cancer (25, 26).